HSCL2023-04-012023-06-30 HSCL2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member HSCL2023-06-30 HSCL2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue01Member HSCL2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue02Member HSCL2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults01Member HSCL2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults02Member HSCL2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets01Member HSCL2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets02Member HSCL2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities01Member HSCL2023-06-30in-bse-fin:OneReportableSegmentLiabilities01Member HSCL2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities02Member HSCL2023-06-30in-bse-fin:OneReportableSegmentLiabilities02Member HSCL2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member HSCL2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500184 HSCL NA Himadri Speciality Chemical Limited Equity 2023-04-01 2024-03-31 2023-07-18 2023-07-11 INR Crores First quarter 18:00:00 19:15:00 2023-07-18 2023-07-18 Not applicable Multi segment 2023-04-01 2023-06-30 Unaudited Standalone 9509100000.00 101200000.00 9610300000.00 6949600000.00 0.00 54600000.00 256500000.00 131100000.00 115700000.00 898400000.00 8405900000.00 1204400000.00 0.00 1204400000.00 210400000.00 117400000.00 327800000.00 0.00 876600000.00 0.00 0.00 0.00 0.00 876600000.00 504500000.00 1381100000.00 0.00 0.00 439000000.00 1 2.02 2.02 0.00 0.00 2.02 2.02 1. The above unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 18 July 2023. A Limited Review of these standalone financial results for the quarter ended 30 June 2023 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LODR) Regulations, 2015. 2. Other expenses includes foreign exchange fluctuation loss/ (gain) (net) of Rs (4.11) crores for the quarter ended 30 June 2023, Rs (3.54) crores for the quarter ended 31 March 2023, Rs 13.63 crores for the quarter ended 30 June 2022 and Rs 19.80 crores for the year ended 31 March 2023, on standalone basis. Finance cost includes exchange difference regarded as an adjustment to borrowing costs in accordance with Ind AS 23, of Re 0.50 crore for the quarter ended 30 June 2023, Re (0.90) crore for the quarter ended 31 March 2023, Rs 4.55 crores for the quarter ended 30 June 2022 and Rs 13.50 crores for the year ended 31 March 2023, on standalone basis. 3. Based on the guiding principles given in Ind AS 108 on 'Operating Segments', the Company's business activity falls within two operating segments, namely: (a) Carbon materials and chemicals, and (b) Power 4. During the previous year, the Company has issued and allotted 72,550,000 warrants, each convertible into one equity share of Re 1 each, on Preferential allotment basis at an issue price of Rs 70 per warrant, to the Promoter/ Promoter Group of the Company and certain identified non-promoter persons / entity, upon receipt of 25% of the issue price (i.e. Rs 17.50 per warrant) as warrant subscription money. Balance 75% of the issue price (i.e. Rs 52.50 per warrant) shall be payable within 18 months from the date of allotment i.e.22 August 2022, at the time of exercising the option to apply for fully paid-up equity share of Re 1 each of the Company, against each warrant held by the warrant holder. During the quarter ended 30 June 2023, the Company upon receipt of balance 75% of the issue price (i.e., Rs 52.50 per warrant) for 6,215,000 warrants, has allotted equal no. of fully paid-up equity shares against conversion of said warrants exercised by the warrant holder. As a result of such allotment, the paid-up equity share capital of the Company has increased from 432,780,659 equity shares to 438,995,659 equity shares of face value of Re 1 each. For the remaining 53,035,000 warrants, the respective allottees have not yet exercised their option for conversion of the warrants into equity shares and accordingly, balance 75% money towards such remaining warrants is yet to be received. The last day for exercising the option for conversion of the warrants into equity shares of the Company is 21 February 2024, being 18 months from the date of allotment of warrants i.e., 22 August 2022. 5.The standalone figures for the three months ended 31 March 2023 as reported in these standalone financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date standalone figures up to the end of the nine months of the relevant financial year. Also the standalone figures up to the third quarter had only been reviewed and not subjected to audit. 6.Earnings per share is not annualised for the quarter ended 30 June 2023, 31 March 2023 and 30 June 2022. 7.The figures of the corresponding previous periods/year have been regrouped/reclassified, wherever necessary, to conform to the classification for the current quarter ended 30 June 2023. Other Expenses 898400000.00 Carbon materials and chemicals 9451400000.00 Power 258200000.00 9709600000.00 200500000.00 9509100000.00 Carbon materials and chemicals 961200000.00 Power 232000000.00 1193200000.00 131100000.00 -142300000.00 Other unallocable expenses net of unallocable income includes other income, foreign exchange loss/ (gain) (net), and exceptional items fully unallocable 1204400000.00 Carbon materials and chemicals 27995500000.00 Power 1100500000.00 29096000000.00 7596500000.00 36692500000.00 Carbon materials and chemicals 4785100000.00 Power 3500000.00 4788600000.00 8147300000.00 12935900000.00 Remeasurements of net defined benefit plan -500000.00 Net gain/ (loss) on investment in equity instruments accounted at fair value 655600000.00 655100000.00 150600000.00 0.00